Abstract
The biological basis for altered fractionation radiotherapy is reviewed in this study. The clinical application of hyperfractionation is based on evidence that late-responding normal tissues are spared more radiation damage than early-responding tissues or tumors when the dose per fraction is decreased to less than 2 Gy. Evidence has also accumulated to indicate that prolonged treatment is detrimental to control tumors due to accelerated repopulation of surviving tumor cells, which is the basis for accelerated fractionation. Recent clinical trials on altered fractionation schedules are also discussed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
